Live Evaluations
Personalized Care for Psoriatic Disease – Addressing Comorbidities: IDS24
About
Personalized Care for Psoriatic Disease - Addressing Comorbidities
This activity is supported by educational grants from Amgen and Lilly.
Learning Objectives
At the completion of this activity, participants should be better able to:
Review the immunopathologic mechanism of psoriatic disease and associated comorbidities
List key therapies to manage psoriatic disease and associated comorbidities
Intended Audience
Faculty
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio Biosciences, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc.
Consultant: Almirall, AltruBio Inc., AnaptysBio, Apogee Therapeutics, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda,Trevi, and Verrica
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.